{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:27:34Z","timestamp":1790630854233,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Genetic mutations contribute to around 10% of breast and 25% of ovarian cancers, with one third of patients having a familial cancer history. The German Consortium for Familial Breast and Ovarian Cancer was founded in 1996 to improve care for these patients. Certification of cancer centers, introduced in 2004, has been linked to improved survival rates and ensures adherence to evidence-based standards. This study investigates changes in care structures and quality before and after the initial certification of the HBOC center at the University Hospital Erlangen, certified from 2021 on.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed patient data from January 2018 to December 2023 at the certified Hereditary Breast and Ovarian Cancer center at the University Hospital Erlangen. Eligibility for genetic counseling and germline testing followed the German Cancer Society criteria. After informed consent, Next Generation Sequencing was performed, and variants were classified according to Human Genome Variation Society and American College of Medical Genetics and Genomics standards. Medical histories and genetic results were recorded in electronic case report forms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 2018 to 2023, a total of 2694 genetic tests were performed, increasing from 962 pre-certification to 1732 post-certification (+\u2009180%). Testing among affected female patients doubled. Genetic testing in breast cancer patients increased from 551 to 1,04, while testing for ovarian carcinoma rose from 117 to 159. Variants of uncertain significance were identified in approximately 9% of cases during both periods. Pathogenic findings were observed in 14.3% of cases pre-certification (with 9.2% involving\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations) and 11.5% post-certification (6.4%\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations). Enrollment in the intensified surveillance program (IBCS) increased by 182.5%, accompanied by a rise in recommendations for risk-reducing surgeries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Certification of medical institutions ensures high-quality, evidence-based patient care and increases the utilization of preventive and counseling services, particularly for Hereditary Breast and Ovarian Cancer. Further studies are needed to confirm the long-term impact and necessity of certification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06388-3","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:35:05Z","timestamp":1765974905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5280-2800","authenticated-orcid":false,"given":"Niklas","family":"Amann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Spannring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Boesl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin C.","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kr\u00fcckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"09","key":"6388_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/a-1222-0042","volume":"80","author":"B Ataseven","year":"2020","unstructured":"Ataseven B et al (2020) Prevalence of BRCA1 and BRCA2 mutations in patients with primary ovarian cancer\u2014Does the German checklist for detecting the risk of hereditary breast and ovarian cancer adequately depict the need for consultation? Geburtshilfe Frauenheilkd 80(09):932\u2013940","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"4","key":"6388_CR2","first-page":"161","volume":"94","author":"MW Beckmann","year":"1997","unstructured":"Beckmann MW et al (1997) Hochrisikofamilien mit mamma- und ovarialkarzinomen: m\u00f6glichkeiten der beratung, genetischen analyse und fr\u00fcherkennung. Dtsch Arztebl Int 94(4):161","journal-title":"Dtsch Arztebl Int"},{"issue":"44","key":"6388_CR3","first-page":"6996","volume":"104","author":"MW Beckmann","year":"2007","unstructured":"Beckmann MW et al (2007) Onkologie dreistufenmodell optimiert behandlung unter kostendeckung wie die k\u00fcnftigen strukturen der onkologischen versorgung in deutschland aussehen sollten. Dtsch Arztebl Int 104(44):6996","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"6388_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000329601","volume":"34","author":"MW Beckmann","year":"2011","unstructured":"Beckmann MW et al (2011) Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie 34(7):362\u2013367","journal-title":"Onkologie"},{"issue":"2","key":"6388_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00117-020-00797-w","volume":"61","author":"U Bick","year":"2021","unstructured":"Bick U (2021) Intensivierte fr\u00fcherkennung mittels magnetresonanztomographie in der hochrisikosituation. Radiologe 61(2):150\u2013158","journal-title":"Radiologe"},{"issue":"1","key":"6388_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-019-05152-9","volume":"175","author":"U Bick","year":"2019","unstructured":"Bick U et al (2019) High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 175(1):217\u2013228","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6388_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12957-023-03262-9","volume":"22","author":"V Bierbaum","year":"2024","unstructured":"Bierbaum V et al (2024) Treatment in certified cancer centers is related to better survival in patients with colon and rectal cancer: evidence from a large German cohort study. World J Surg Oncol 22(1):11","journal-title":"World J Surg Oncol"},{"key":"6388_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.zefq.2020.11.008","volume":"160","author":"S Deckert","year":"2021","unstructured":"Deckert S et al (2021) Methodological standard for the development of quality indicators within clinical practice guidelines\u2014Results of a structured consensus process. Z Evid Fortbild Qual Gesundhwes 160:21\u201333","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"6388_CR9","unstructured":"DKG (2025) Jahresbericht der zertifizierten zentren f\u00fcr famili\u00e4ren brust-und eierstockkrebs\u2014Kennzahlenauswertung 2025."},{"issue":"1","key":"6388_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N et al (2019) Breast cancer. Nat Rev Dis Primers 5(1):66","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"6388_CR11","doi-asserted-by":"publisher","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P et al (2017) Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE 12(10):e0186043","journal-title":"PLoS ONE"},{"issue":"3","key":"6388_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00384-020-03792-8","volume":"36","author":"A Jacob","year":"2021","unstructured":"Jacob A et al (2021) Association of certification, improved quality and better oncological outcomes for rectal cancer in a specialized colorectal unit. Int J Colorectal Dis 36(3):517\u2013533","journal-title":"Int J Colorectal Dis"},{"issue":"7","key":"6388_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103672","volume":"53","author":"K Kast","year":"2016","unstructured":"Kast K et al (2016) Prevalence of <em>BRCA1\/2<\/em>germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet 53(7):465\u2013471","journal-title":"J Med Genet"},{"issue":"Onkologie 3","key":"6388_CR14","first-page":"22","volume":"117","author":"K Kast","year":"2020","unstructured":"Kast K et al (2020) Famili\u00e4rer brust- und eierstockkrebs: zielgerichtete und abgestufte pr\u00e4ventionsstrategien. Dtsch Arztebl Int 117(Onkologie 3):22","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"6388_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12312-024-01334-9","volume":"39","author":"K Klein","year":"2024","unstructured":"Klein K et al (2024) Fr\u00fchzeitige Identifikation einer famili\u00e4ren Krebsbelastung. Forum 39(4):285\u2013288","journal-title":"Forum"},{"issue":"2","key":"6388_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-0031-1280475","volume":"72","author":"C Kowalski","year":"2012","unstructured":"Kowalski C et al (2012) The patients\u2019 view on accredited breast cancer centers: strengths and potential for improvement. Geburtshilfe Frauenheilkd 72(2):137\u2013143","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"6388_CR17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1186\/s12885-017-3824-1","volume":"17","author":"C Kowalski","year":"2017","unstructured":"Kowalski C et al (2017) Shifting cancer care towards multidisciplinarity: the cancer center certification program of the German cancer society. BMC Cancer 17(1):850","journal-title":"BMC Cancer"},{"key":"6388_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.breast.2018.04.002","volume":"40","author":"R Kreienberg","year":"2018","unstructured":"Kreienberg R, W\u00f6ckel A, Wischnewsky M (2018) Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: an evaluation of 8323 patients. Breast 40:54\u201359","journal-title":"Breast"},{"issue":"3","key":"6388_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00404-010-1398-0","volume":"283","author":"MP Lux","year":"2011","unstructured":"Lux MP et al (2011) The era of centers: the influence of establishing specialized centers on patients\u2019 choice of hospital. Arch Gynecol Obstet 283(3):559\u2013568","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"6388_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10549-016-3805-0","volume":"157","author":"D Madorsky-Feldman","year":"2016","unstructured":"Madorsky-Feldman D et al (2016) An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319\u2013327","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6388_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12962-021-00273-9","volume":"19","author":"A Modabber","year":"2021","unstructured":"Modabber A et al (2021) Impact of quality certification of multidisciplinary head and neck tumor centers. Cost Eff Resour Alloc 19(1):20","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"6388_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00432-025-06288-6","volume":"151","author":"O Ortmann","year":"2025","unstructured":"Ortmann O et al (2025) Correlation of surgical volume in gynecological cancer centers with the quality of ovarian cancer care. J Cancer Res Clin Oncol 151(8):239","journal-title":"J Cancer Res Clin Oncol"},{"issue":"25","key":"6388_CR23","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428","journal-title":"N Engl J Med"},{"issue":"1","key":"6388_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12885-022-09731-w","volume":"22","author":"M Roessler","year":"2022","unstructured":"Roessler M et al (2022) Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. BMC Cancer 22(1):621","journal-title":"BMC Cancer"},{"issue":"08","key":"6388_CR25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1055\/a-1877-4332","volume":"76","author":"R Schirrmacher","year":"2022","unstructured":"Schirrmacher R, Rieger B, Justenhoven C (2022) Behandlung in zertifizierten lungenzentren (DKG)\u2014Entscheidungsfaktoren von patienten mit lungenkrebs. Pneumologie 76(08):547\u2013551","journal-title":"Pneumologie"},{"issue":"39","key":"6388_CR26","first-page":"647","volume":"120","author":"J Schmitt","year":"2023","unstructured":"Schmitt J et al (2023) Initial cancer treatment in certified versus non-certified hospitals. Dtsch Arztebl Int 120(39):647\u2013654","journal-title":"Dtsch Arztebl Int"},{"issue":"50","key":"6388_CR27","first-page":"6514","volume":"102","author":"K Schmutzler","year":"2005","unstructured":"Schmutzler K et al (2005) Famili\u00e4rer brust- und eierstockkrebs: von der forschung zur regelversorgung. Dtsch Arztebl Int 102(50):6514","journal-title":"Dtsch Arztebl Int"},{"key":"6388_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-025-08028-0","author":"N Tauber","year":"2025","unstructured":"Tauber N et al (2025) Therapy of early breast cancer: current status and perspectives. Arch Gynecol Obstet. https:\/\/doi.org\/10.1007\/s00404-025-08028-0","journal-title":"Arch Gynecol Obstet"},{"issue":"25","key":"6388_CR29","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"2","key":"6388_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1148\/radiol.2017161218","volume":"285","author":"JCM van Zelst","year":"2017","unstructured":"van Zelst JCM et al (2017) Surveillance of women with the BRCA1 or BRCA2 mutation by using biannual automated breast US, MR imaging, and mammography. Radiology 285(2):376\u2013388","journal-title":"Radiology"},{"issue":"1","key":"6388_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00404-013-3084-5","volume":"289","author":"S Wesselmann","year":"2014","unstructured":"Wesselmann S, Beckmann MW, Winter A (2014a) The concept of the certification system of the German Cancer Society and its impact on gynecological cancer care. Arch Gynecol Obstet 289(1):7\u201312","journal-title":"Arch Gynecol Obstet"},{"issue":"11","key":"6388_CR32","first-page":"464","volume":"90","author":"S Wesselmann","year":"2014","unstructured":"Wesselmann S, Benz S, Graeven U (2014b) Qualit\u00e4tssicherung in der onkologie\u2014Zertifizierte netzwerke f\u00fcr patienten. Z Allg Med 90(11):464\u2013468","journal-title":"Z Allg Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06388-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06388-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06388-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:35:10Z","timestamp":1765974910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06388-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6388"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06388-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7761592\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.A. received honoraria for lectures and participation in advisory boards: Gilead, Georg Thieme Verlag. N.A. also received support for attending meetings from AstraZeneca, Novartis, Pfizer; M.H. received research support from Helsinn Healthcare SA, honoraria from Lilly Deutschland GmbH, Thieme and travel support from Novartis, Lilly Deutschland GmbH, and AstraZeneca. H.S. no conflicts of interests. L.B. received support for attending meetings from AstraZeneca; J.G. no conflicts of interests. S.N. no conflicts of interests. C.M. received honoraria for research from Novartis. F.H. no conflicts of interests. C.C.H. J.G. no conflicts of interests. P.A.F received personal fees from Novartis, Pfizer, Daiichi-Sankyo, Astra Zeneca, Eisai, Merck Sharp & Dohme, Lilly, SeaGen, Roche, Agendia, Gilead, Mylan, Menarini, Veracyte, GuardantHealth, and grants from Biontech, Pfizer, Cepheid, during the conduct of the study; and Translational Research in Oncology (TRIO). M.W.B. no conflicts of interests. AK received lecture fees from Gilead and Novartis, honoria for written scientific work from Georg Thieme Verlag as well as support for attending meetings from Lilly","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of the Faculty of Medicine at Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) (ref. number 24-440-Br). All procedures were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Supplemental agreement to the study was waived due to the retrospective study design including only anonymized data analysis. There was no use of animal research within this project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"13"}}